BNGO - From Lab Bench to Wall Street Buzz Bio
Post# of 80

Bionano’s true value lies beneath the surface. It’s not just a device maker — it’s the foundation of a worldwide genomic infrastructure. As Wall Street catches on, early believers stand to benefit most.
Diagens (China): A pioneering Bionano Genomics partner bringing AI-driven chromosome analysis into reproductive health across Chinese hospitals. It’s already approved for clinical use in China, a major regulatory milestone.
BioDiscovery (USA): Acquired to strengthen Bionano’s software strategy. Its clinical platform merges optical genome mapping with sequencing data, giving geneticists unmatched insight into structural variants.
Lineagen (USA): Now operating as Bionano Laboratories, it provides clinically certified diagnostics for children with neurodevelopmental disorders, a vital step toward insurance reimbursement and mainstream medical adoption.
Revvity (Global): A strategic collaboration expands Bionano’s software into newborn sequencing workflows worldwide, embedding the company into clinical genomics from day one.
Hamilton (Switzerland): Co-developed the Long String VANTAGE workstation with Bionano — the first fully automated system for extracting ultra-high molecular weight DNA, a prerequisite for optical genome mapping. Hamilton’s global reputation in precision liquid handling makes this partnership a vote of confidence in Bionano’s tech.
Tecan (Switzerland): OEM partner supporting automation of Bionano’s workflows, including DNA extraction and sample prep. Tecan’s platforms are widely used in genomics labs worldwide, and its collaboration with Bionano positions OGM for plug-and-play integration into existing infrastructure.

